Welcome to our dedicated page for Health In Tech SEC filings (Ticker: HIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health In Tech, Inc. filings document material-event disclosures for a Nevada operating company with Class A common stock listed on the Nasdaq Capital Market under HIT. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD materials, investor presentations and conference-call transcripts.
The filing record also addresses capital-structure matters, including a private investment in public equity financing, and governance disclosures involving executive officer departures, compensatory arrangements and related consulting agreements. The company identifies as an emerging growth company in its Exchange Act reports.
Health In Tech (HIT) disclosed an initial insider ownership filing on Form 3 for Michael Clarkson, the company’s CISO. The filing states that no securities are beneficially owned by the reporting person as of the event date 11/01/2025.
The Form 3 was filed by one reporting person in the capacity of an officer. No non-derivative or derivative holdings were reported.
Insider transactions by director William D. Howard at Health In Tech, Inc. (HIT)
The reporting person, a director, disposed of 28,159 restricted shares of Class A common stock that were subject to pro-rata forfeiture upon the annual stockholders meeting held on 10/03/2025. Five days later, on 10/08/2025, the director acquired 5,730 restricted shares at a price of $3.49 per share under the company’s Equity Incentive Plan. After these transactions the director beneficially owns 106,045 shares of Class A common stock.
Insider transactions by Director Timothy Hayes at Health In Tech, Inc. (HIT)
Director Timothy Hayes reported a disposition and a later acquisition of Class A common stock. On 10/03/2025 he disposed of 28,159 restricted shares that were forfeitable pro rata at the issuer's annual meeting, leaving 100,315 shares beneficially owned. On 10/08/2025 he acquired 5,730 restricted shares at a purchase price of $3.49 per share; those newly granted restricted shares vest quarterly from the grant date subject to continued service. The filing shows Hayes remains a significant insider and that his post-transaction holdings total 106,045 shares, combining previously owned and newly granted restricted stock.
Insider transactions by Director Sanjay K. Shrestha at Health In Tech, Inc. (HIT). The form reports a disposition of 65,469 Class A common shares on 10/03/2025 that were restricted shares subject to forfeiture tied to the annual stockholders meeting. The filing also shows an acquisition of 5,730 restricted Class A shares on 10/08/2025 at a purchase price of $3.49 per share; those restricted shares vest quarterly from the grant date with continued service. After these transactions the reporting person beneficially owned 68,735 Class A shares on a direct basis.
Health In Tech, Inc. reported results of its 2025 annual stockholder meeting. As of the August 6, 2025 record date, 56,389,291 shares were outstanding, split between 44,689,291 Class A shares with one vote each and 11,700,000 Class B shares with ten votes each.
Stockholders representing about 99.33% of voting power, or 161,619,722 votes, were present, establishing a strong quorum. All five director nominees were re-elected with roughly 148 million votes cast in favor for each and minimal abstentions, with broker non-votes of 1,873,265.
Stockholders approved an amendment to the 2024 Equity Incentive Plan, raising the Class A share reserve for awards from 7,677,849 to 10,677,849 and allowing issuance of up to 2,000,000 Class B shares and related options to executive officers. They also ratified MaloneBailey, LLP as independent auditors for the year ending December 31, 2025, with 161,551,973 votes for, 33,314 against, and 34,446 abstentions.
Health In Tech, Inc. (HIT) reported an insider grant to Tim Johnson, who is the company's Chief Executive Officer, a director and a >10% owner. On 09/24/2025 Mr. Johnson was granted 80,000 restricted shares of Class A Common Stock under the Health in Tech Equity Incentive Plan at no cash price. The restricted shares vest in three equal tranches, each vesting monthly over a 12-month period tied to milestones: signing a letter of intent or MOU for an initiative, proof-of-concept or beta launch, and full commercial launch. After the grant Mr. Johnson beneficially owns 22,549,741 shares (which the form notes includes 137,495 restricted shares and 22,412,246 Class A shares); the filing excludes 9,000,000 Class B shares and 734,707 options.
Health In Tech, Inc. reported that its Compensation Committee approved new restricted stock awards for its two top executives tied to a specific new business initiative. On September 24, 2025, the company granted 80,000 shares of restricted stock to Chief Executive Officer Tim Johnson and 80,000 shares of restricted stock to Chief Financial Officer Linlin (Julia) Qian. These awards are meant to compensate them for work on a new initiative described as the “Initiative.”
Each grant is structured so that one third of the shares vest in monthly installments over 12 months starting when a letter of intent or memorandum of understanding is signed, another third vests monthly over 12 months starting when the Initiative reaches proof-of-concept or beta launch, and the final third vests monthly over 12 months starting at full commercial launch. The awards were made under the company’s existing Equity Incentive Plan and follow previously approved restricted stock award agreement terms.
LinLin Qian, who serves as Chief Financial Officer, a director and a >10% owner of Health In Tech, Inc. (HIT), received a grant of 80,000 restricted shares of Class A Common Stock on 09/24/2025 at a reported price of $0. Following the grant, the reporting person beneficially owns 8,128,555 shares, which the filing states includes 130,495 restricted shares and 7,998,060 Class A shares (the filing separately excludes 2,700,000 Class B shares and 711,510 options). The restricted shares vest in three equal tranches tied to an initiative: monthly over 12 months after a letter of intent, monthly over 12 months after proof-of-concept or beta launch, and monthly over 12 months after full commercial launch.
Health In Tech, Inc. is soliciting votes for its annual meeting and has mailed a Proxy Statement and Annual Report to holders of record as of August 6, 2025. The filing outlines meeting logistics, voting procedures (including a telephonic proxy deadline of 11:59 p.m. ET on October 2, 2025), broker voting treatment for "routine" items, and deadlines for stockholder proposals and director nomination notices for the 2026 meeting (May 13, 2026 for proposals; August 4, 2026 for contested-nomination notices under Rule 14a-19).
The statement identifies the company's executive officers and board members, describes committee charters and responsibilities (audit, compensation, nominating/governance), discloses a related-party services amounting to $940,915 through May 31, 2023, and notes corporate actions including a retroactive stock split effected June 4, 2024. Director compensation includes an $80,000 restricted stock award for non-employee directors vesting after one year. The Audit Committee reports pre-approval of Malone Bailey's 2024 services.
Health In Tech, Inc. (HIT) reporting person LinLin Qian, who serves as Chief Financial Officer, Director and a reported 10% owner, received a grant of 27,000 restricted shares of Class A Common Stock on 08/15/2025. The restricted shares were issued under the Health in Tech Equity Incentive Plan and vest based on operational milestones: 50% vest monthly over 12 months after the first specified program is launched and operational, and the remaining 50% vest monthly over 12 months after the second specified program is launched and operational. Following the transaction the reporting person beneficially owns 8,048,555 shares (which the filing states include 55,193 restricted shares and 7,993,362 Class A shares), while the filing excludes certain Class B shares and options.